ReviewCurrent genetic medicine reports2014
After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents.
Review in Current genetic medicine reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Trial
- Health Care Equity andHealth equity · 2025Article
- Review
- Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer.JCO oncology practice · 2022Article
- Homologous Recombination Deficiencies and Hereditary Tumors.International journal of molecular sciences · 2021Review
- Review
- Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.Journal of cancer education : the official journal of the American Association for Cancer Education · 2021Article
- Molecular Features and Clinical Management of Hereditary Gynecological Cancers.International journal of molecular sciences · 2020Review
- A Commentary on Commercial Genetic Testing and the Future of the Genetic Counseling Profession.Journal of genetic counseling · 2018Article
- Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Article
- From Gutenberg to Open Science: An Unfulfilled Odyssey.Drug development research · 2017Article
- Myriad's impact on gene patents.Nature biotechnology · 2016Article
- How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2016Review
- Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?Genome medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genetic testing is becoming more common and more powerful by the day. The costs of the underlying DNA sequencing technology are plummeting, making it likely that tests based on it will become even more pervasive. The use of tests to determine DNA sequence to help make clinical decisions is here to stay. DNA sequencing is also finding new uses in forensics, determination of ancestry, understanding the history and genetic lineages of human populations and many other applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.